Artificial intelligence news.
Straight from the original announcements.

Bracco Wins FDA Clearance for AI Brain Aneurysm Software

November 13, 2026, 08:00By the AI News Bites Editorial TeamSource: PR Newswire
Bracco Wins FDA Clearance for AI Brain Aneurysm Software
Image: PR Newswire

Bracco and Avicenna.AI have received U.S. Food and Drug Administration 510(k) clearance for UPTUNITY™ | Aneurysm, an AI-enabled software tool for detecting and assessing brain aneurysms on cerebral arteries computed tomography angiography images.

Key points
  • UPTUNITY | Aneurysm received FDA 510(k) clearance.
  • The software detects suspected saccular aneurysms greater than 3 mm on head CTA images.
  • Its MIMPS function compares quantitative measurements across examinations.
  • Avicenna.AI will lead promotion and commercial distribution in the United States.
  • The product will be showcased at the RSNA 2026 Annual Meeting.

AI assistance for detection and follow-up

UPTUNITY™ | Aneurysm is the first offering in Bracco's new UPTUNITY™ portfolio of AI-enabled clinical decision support solutions. The software is designed to integrate AI assistance into the radiologist's existing reading workflow.

Its detection functions identify suspected saccular brain aneurysms greater than 3 mm on head CTA images. The system provides information about a suspected aneurysm's presence, location and size to support assessment and characterization by appropriately trained medical specialists.

For patients with known aneurysms, the software's follow-up functionality, called MIMPS, provides quantitative measurements and comparisons between examinations. This is intended to help assess changes over time, extending the workflow from initial identification through longitudinal follow-up.

Physicians remain responsible for clinical decisions

Bracco said the software is intended to be used as a concurrent reading aid alongside review of CTA images. It maintains physician control over clinical decision-making and is not intended to replace a full patient evaluation or a qualified physician's review.

The company also states that UPTUNITY | Aneurysm should not be solely relied upon to make or confirm a diagnosis. The product is aimed at a clinical problem that can be difficult to identify: brain aneurysms are often asymptomatic, may be discovered incidentally during imaging for other concerns, and can require consistent follow-up.

According to the source, an estimated one in 50 U.S. adults has an unruptured brain aneurysm. Cosimo DePinto, Bracco Americas' Executive Vice President, Marketing & Commercial Operations, said, “A small incidental aneurysm on a head CTA can easily be overlooked when the worklist keeps growing.”

Part of Bracco's broader digital health strategy

Bracco said UPTUNITY expands its Digital Health strategy into interpretive AI and complements existing offerings such as AiMIFY®, developed with Subtle Medical. AiMIFY applies AI to amplify existing contrast enhancement in brain MRI for improved lesion visualization.

Bracco and Avicenna.AI announced their strategic partnership in March 2026 to advance AI applications in contrast-enhanced computed tomography. Avicenna.AI will lead promotion and commercial distribution as the companies prepare for the commercial introduction of UPTUNITY | Aneurysm in the United States.

The software has received 510(k) clearance under K262062 and K262147. The companies will showcase it at the Radiological Society of North America 2026 Annual Meeting in Chicago, taking place November 29 through December 3. The clearance gives radiologists a tool designed to support both the first review of a CTA scan and the comparison of later examinations, while leaving diagnosis and treatment decisions with physicians.

BraccoAvicenna.AIUPTUNITYFDAhealthcare

Related news

Withings Body Pro 3 brings segmental body composition tracking home
Products and toolsNovember 12, 2026, 13:15

Withings Body Pro 3 brings segmental body composition tracking home

Withings Health Solutions has unveiled Body Pro 3, a cellular health station designed to give weight management and GLP-1 programs more information than a conventional…

Research
ResearchNovember 3, 2026, 11:48

Differentia Bio's AI models matched later clinical outcomes

Differentia Bio says its disease-modeling platform identified therapeutic mechanisms between 2023 and 2024 that were later supported by independent clinical results. One…

DxCheck Launches DxPro, a Free AI Workspace for Verified U.S. Clinicians
Products and toolsOctober 29, 2026, 13:13

DxCheck Launches DxPro, a Free AI Workspace for Verified U.S. Clinicians

DxCheck has launched DxPro, an AI-powered workspace for practicing U.S. healthcare professionals that combines cited clinical answers, daily specialty updates and…